Las Vegas, NV -- (SBWIRE) -- 01/08/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Cannabis Science Inc(OTCMKTS:CBIS), Marina Biotech, Inc.(OTCMKTS:MRNA), AMARANTUS BIOSCIENCE HOLDINGS, INC.(OTCBB:AMBS), Endocan Corp(OTCMKTS:ENDO)
Cannabis Science Inc(OTCMKTS:CBIS) increased 13.60% at the price of $0.785 recently on a traded volume of 23.29 million shares, in comparison to 11.85 million shares of average trading volume. So far this year, the stock is up over 51.49%.
The company has a total market capitalization of $59.38 million and its total outstanding shares are 761.32 million. annabis Science, Inc. is a development-stage company. Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.
For How Long CBIS will Fight for Profitability? Read This Trend Analysis report
Marina Biotech, Inc.(OTCMKTS:MRNA) soared 6.98% at the trading price of $0.460 on a traded volume of 11,154.00 shares till now, whereas its average trading volume is 130,545.00 shares. In the last three months, the stock is up 71.71%. The Intra-day range for the stock is $0.43and $0.47. Marina Biotech, Inc. is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference (RNAi) and blocking messenger RNA (mRNA) translation. The Company's pipeline includes a clinical program in Familial Adenomatous Polyposis (FAP) and preclinical programs in bladder cancer and myotonic dystrophy
For How Long MRNA Gloss will Attract Investors? Find out via this report
AMARANTUS BIOSCIENCE HOLDINGS, INC.(OTCBB:AMBS) dropped down -1.33% at the $0.074recently. The 52-week range for the stock is $0.027 and $0.16. Its introductory price for the day was $0.075, with the overall traded volume of 4.16million shares. Amarantus BioScience Holdings, Inc., a development-stage biotechnology company, focuses on the discovery and development of drug candidates and diagnostic blood tests to diagnose and treat human diseases in the United States.
Why Should Investors Buy AMBS After the Recent Fall? Just Go Here and Find Out
Endocan Corp(OTCMKTS:ENDO) after opening its shares at the price of $0.05, jumped up 20.41% , its recent trading price was $0.0590 for the day. The stock moved on a traded volume of 3.23 million shares, in comparison to 1.02million shares of average trading volume.
The 52-week range for the stock is $0.02 and $0.05. Its introductory price for the day was $0.05. Endocan Corp, formerly The X-Change Corporation offers nutraceuticals and cosmetics in the United States. The Company provides lip balms, eczema moisturizing cream, sunscreen, and anti-ageing serum under the Phytiva brand name. The Company specializes in developing all natural, organic, bio hemp health, beauty, and cosmetics products.
Why Should Investors Buy ENDO After The Recent Gain? Just Go Here and Find Out
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)